Drugs / LY06006
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT04973722 | Dec 2020 → Apr 2021 | — | Luye Pharma Group Ltd. | Unknown | No outcome recorded |
| Phase 1 | NCT03427853 | Jan 2018 → Dec 2019 | — | Luye Pharma Group Ltd. | Unknown | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT05060406 | Jun 2019 → Sep 2021 | postmenopausal osteoporosis | Luye Pharma Group Ltd. | Unknown | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LY06006 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04973722 ↗ |
| Known as | denosumab | “The objectives are to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and immunogenicity of denosumab injection (code name:LY06006).” NCT03427853 ↗ |
| Action | Inhibit | “recombinant human monoclonal anti-RANKL antibody injection” NCT05060406 ↗ |
| Modality | Monoclonal antibody | “recombinant human monoclonal anti-RANKL antibody injection” NCT05060406 ↗ |
| Route | Subcutaneous | “denosumab injection administered subcutaneously to healthy adults in China” NCT03427853 ↗ |